The Disregard of Preclinical R&D Software Is Hurting Science—but There’s Hope (Part 3 of 3)
Read how the lack of software innovation for preclinical R&D exacerbates pharma’s productivity crisis, and what we can do to address it.
Venture Capital’s Unfounded Fear of Preclinical R&D Software Hurts Science (Part 2 of 3)
Investors have mistakenly avoided the preclinical R&D software market. This is the key reason it languishes. And why the opportunity is so untapped.
Software Isn’t Eating Preclinical R&D, and That’s a Problem (Part 1 of 3)
Bench scientists doing preclinical R&D for diseases like COVID-19 haven’t benefited equally from the productivity software revolution. This must change.